After Hours
$
20.34
Change
-0.50 -2.40%
Volume
Volume 9,940
Sep 26, 2023, 6:43 p.m.
Quotes are delayed by 20 min
Previous close
$ 19.26
$ 20.84
Change
+1.58 +8.20%
Day low
Day high
$19.21
$20.99

52 week low
52 week high
$16.52
$59.99

Market cap
$1.15B
Average volume
2.01M
P/E ratio
N/A
Rev. per Employee
$15,054
EPS
-9.93
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on SAGE
-
Sage Therapeutics stock price target cut to $19 from $45 at Mizuho
- Tomi Kilgore
-
Split FDA Call on Depression Drug Upsets Strategies for Biogen, Sage
- Barron's Online
-
Sage downgraded to neutral from outperform at Wedbush
- Tomi Kilgore
-
Sage Therapeutics downgraded to perform from outperform at Oppenheimer
- Tomi Kilgore
-
Sage Therapeutics’ stock slides 49% premarket on disappointment at FDA decision on depression treatment
- Ciara Linnane
-
FDA approves first-ever pill for postpartum depression in new mothers
- Rachel Koning Beals
-
Reata Stock Surges. Biogen Is Buying It for $7.3 Billion in Cash.
- Barron's Online
-
Biogen to slash 1,000 jobs as it looks to save $700 million
- Eleanor Laise
-
Biogen Earnings Beat Expectations. All Eyes Are on the Alzheimer's Drug.
- Barron's Online
-
Price Negotiations Are About to Reshape the Drug Industry
- Barron's Online
- Loading more headlines...
Analyst Ratings
-
Benzinga's Top Upgrades, Downgrades For February 26, 2018
- Benzinga.com
-
Cowen Raises Sage Value On New Phase 2 Trial Success
- Benzinga.com
Other News on SAGE
-
First Pill for Postpartum Depression Is Approved by FDA
- The Wall Street Journal Interactive Edition
-
- Edgar Online - (EDG = 10Q, 10K)
-
- Edgar Online - (EDG = 10Q, 10K)
-
Biogen Boss Turns Corner on Alzheimer’s Miscues
- The Wall Street Journal Interactive Edition
-
Sage Therapeutics, Inc. (SAGE) Q3 2022 Earnings Call Transcript
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
Why Doctors Are Studying New Drugs to Treat Women’s Midlife Mood Swings
- The Wall Street Journal Interactive Edition
Press Releases on SAGE
-
Sage Therapeutics to Present at Upcoming May Investor Conferences
- BusinessWire - BZX
-
Sage Therapeutics to Present at the Stifel 2023 CNS Days
- BusinessWire - BZX
-
Sage Potash Announces Exchange Listing
- ACCESSWIRE
-
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
- BusinessWire - BZX
-
Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
- BusinessWire - BZX
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com